Eurofarma Laboratorios
As of the edition of 20 October 2026, Eurofarma Laboratorios runs 26 drugs, 16 of them marketed; it is on route A at 1 target and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 16 |
| Active | 2 |
| Stopped | 8 |
| Total | 26 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Filgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Levetiracetam | none listed | 3 |
| Enoxaparin sodium | none listed | 3 |
| Heparin | none listed | 5 |
| Dacarbazine | none listed | 0 |
| Meloxicam | none listed | 1 |
| Desloratadine | none listed | 3 |
| Eszopiclone | none listed | 0 |
| Danazol | none listed | 2 |
| Udenafil | none listed | 0 |
| Cenobamate | Ends 2032 (patent) | 0 |
| Cefdinir | none listed | 0 |
| Aceclofenac | none listed | 0 |
| Penicillin v | none listed | 0 |
| Ebastine | none listed | 0 |
| Bromopride | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 3 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Eurofarma Laboratorios needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 6 trials led
- Digestive system: 5 trials led
- Hormones: 4 trials led